Cullinan Therapeutics, Inc. $CGEM Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) by 347.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,310 shares of the company’s stock after buying an additional 58,488 shares during the period. The Manufacturers Life Insurance Company’s holdings in Cullinan Therapeutics were worth $1,070,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in CGEM. Caitong International Asset Management Co. Ltd boosted its stake in Cullinan Therapeutics by 62.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock valued at $28,000 after acquiring an additional 1,036 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Cullinan Therapeutics in the 4th quarter valued at about $31,000. CWM LLC raised its stake in shares of Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company’s stock valued at $40,000 after purchasing an additional 1,318 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock worth $62,000 after purchasing an additional 2,523 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Cullinan Therapeutics during the fourth quarter worth about $99,000. 86.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $17.82, for a total transaction of $142,560.00. Following the completion of the transaction, the insider owned 162,844 shares in the company, valued at $2,901,880.08. The trade was a 4.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Cullinan Therapeutics in a report on Thursday, June 11th. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Wednesday, July 8th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Cullinan Therapeutics in a report on Monday, June 8th. Finally, BTIG Research upped their price target on Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cullinan Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

Cullinan Therapeutics Stock Down 0.2%

Shares of NASDAQ CGEM opened at $19.60 on Thursday. The firm’s 50-day moving average price is $16.81 and its two-hundred day moving average price is $14.99. Cullinan Therapeutics, Inc. has a 52-week low of $5.68 and a 52-week high of $19.94. The stock has a market capitalization of $1.26 billion, a P/E ratio of -6.32 and a beta of 0.01.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.01). As a group, equities research analysts expect that Cullinan Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Cullinan Therapeutics News Summary

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $30 target for Cullinan Therapeutics (CGEM). The target remains meaningfully above the recent share price, providing a bullish valuation signal and likely supporting the stock’s recent strength.
• Neutral Sentiment: The analyst expects Cullinan to remain unprofitable but sees quarterly losses narrowing gradually in 2027, with estimated EPS of $(0.77) in Q1, $(0.78) in Q2, $(0.80) in Q3 and $(0.82) in Q4. Full-year 2027 EPS is projected at $(3.17), compared with an estimated $(3.53) loss in 2026.
• Neutral Sentiment: A reported short-interest figure of zero shares and a zero-day days-to-cover ratio offers no meaningful indication of bearish positioning. The data appears unreliable or incomplete rather than evidence of an absence of short sellers.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a $(3.53) loss from $(3.42), cut Q3 2026 EPS to $(0.90) from $(0.87), and reduced Q4 2026 EPS to $(0.93) from $(0.90). These revisions point to weaker-than-previously-expected profitability and could limit gains despite the bullish price target.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.